Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.
Introduction
Pharmacovigilance (PV) plays a vital role to ensure patient safety. The World Health Organization (WHO) defines 'pharmacovigilance' as a process of detection, monitoring and preventing drug-related harm [1] . Adverse Drug Reaction (ADR) reporting is the cornerstone of PV. The WHO defines ADR as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function" [2] .
ADRs are major global issue, adversely impacting patient safety and health outcomes; they are ranked as fourth and seventh leading cause of death in United States and Sweden, respectively [3, 4] . Due to significant under-reporting and vast heterogeneity in the use of definitions, data collection methods, the incidence and prevalence of ADRs vary considerably across countries, ranging from 16% among studies performed in United Kingdom (UK) [5] to 38% in Germany [6] , 6% in South Africa [7] , to 4.5 and 10.2% among studies performed in Saudi Arabia [8] and United Arab Emirates (UAE) [9] . A meta-analysis (1998) to determine the incidence of ADRs among hospitalized patients suggested that ADRs affected over 2 million patients at an estimated cost of $130 billion annually in the United States (US) alone [10] .
PV practices in Qatar are evolving rapidly and ADR reporting systems have undergone significant changes over the last few years. Despite all the recent developments, there is scarcity of published evidence relating to ADR reporting in Qatar. This article explores organizational structure, PV practices and provides information about how ADRs are identified, reported, analyzed and interpreted at a healthcare level. It also provides blueprint of a Medication Safety Center at the largest academic healthcare system in Qatar.
Healthcare system in Qatar
Qatar is a small peninsula occupying 11,437 km 2 of land area and has a total population of 2.6 million, of which only 15% are native Qataris [11] . The quality of healthcare delivery in Qatar is of very high standards with annual healthcare budget exceeding $3071 per capita (2.2% of GDP) in 2014, one of the highest in the region. The Ministry of Public Health (MoPH) is Qatar's highest health authority, responsible to plan and advise on the national healthcare priorities, to regulate and monitor healthcare systems and provide services to meet the national healthcare needs. Unlike other high-income countries where people are the main source of healthcare funding, healthcare costs in Qatar are predominantly financed by government revenues, by providing free treatment to the nationals and heavily subsidized treatment options to the residents [12] .
Under the regulation of MoPH, the healthcare system in Qatar is primarily divided into private and public healthcare sectors. The current structure of healthcare services can be found in Fig. 1 .
National Health Strategy 2011-2016
Improving patient safety through 'safe use of medication' is a core component of Qatar's National Health Strategy (NHS) 2011-2016 [14] . NHS advocates developing a world-class healthcare system by ensuring safe and effective use of medications and healthcare products. Establishing a specialized Medication Safety and Quality Center (MSQC) at Hamad Medical Corporation (HMC), the tertiary and academic healthcare provider within MoPH, to monitor the safe and effective use of medications, is one of the key strategies to achieve the goals set by the NHS. 
Establishing HMC's Medication Safety and Quality Centre (MSQC)
Since 2016, MSQC is recognized as a center to monitor medication safety practices within HMC, which in turn created a community of medication safety experts within the healthcare system.
How it started?
To better understand the nature and scope of medicationrelated harm, improve the current medication safety practices, and further strengthen the PV activities, the 
ADR reporting policy
HMC has adopted WHO definition of ADRs. ADR reporting at HMC is policy-driven and has migrated from a paperbased system to an electronic system (Cerner ® ). HMC's policy on suspected ADR reporting and monitoring requires all ADRs to be documented in patients' medical records and to be reported immediately. However, data about the quality, nature and extent of these reports are lacking. Anecdotal evidence indicates that healthcare professionals have different attitudes and affinities to document and report ADRs and there are possibilities of gross under-reporting. 
Spontaneous ADR

ADR reporting and data acquisition at HMC
The ADR reporting process at HMC is centralized, whereby all suspected ADRs are reported by HCPs (mostly pharmacists, nurses and doctors) electronically. Any drug related problem that implies a causal relation between the drug and the adverse reaction must be reported, with details about the drug, reaction, timings and interventions. The ADR reporting process at HMC is illustrated in Fig. 2 . Reports are then reviewed by the hospital specific MSOs and are further classified based on causality, severity, and preventability using different tools (Causality-Naranjo Causality Scale, Severity-Hartwig's Severity Scale, Preventability-Schumock and Thornton Preventability). Once completed, these reports are forwarded to the corporate office (MSQC), where the reports are reviewed and pooled for any potential causal relationship. MSQC generates a monthly report to the pharmacy executive director who then disseminates the findings to MoPH, Quality and Patient Safety Committee (QPS), Risk Management Committee and to other key stakeholders (Qatar University, patient safety departments etc.,) for further actions. Furthermore, all clinically relevant ADRs are disseminated to healthcare professionals (HCPs) through presentations, discussions and monthly newsletters. The dissemination of such information leads to institutional and individual learning and a continuous improvement of patient safety and change in practice.
Memberships and affiliations
HMC is the only academic health system outside the US to have all its hospitals accredited by the Joint Commission International (JCI), demonstrating its commitment to continuous delivery of safe, high-quality care [15] . Moreover, in collaboration with the Institute for Healthcare Improvement (IHI), HMC is committed to provide the safest, most effective and most compassionate care to each and every patient [16] . MSQC within HMC is a full member of the International Medication Safety Network (IMSN), an international organization committed to prevent medication-related harm and contribute to safer healthcare [17] . Qatar is also an associate member of the WHO Program for International Drug Monitoring [18] . Table 1 , approximately 92% of reported ADRs were 'mild-moderate' in severity scale, whilst less than 9% were 'severe'. Nearly 88% were 'non-preventable'. Majority of ADRs were reported by pharmacists (57.3%).
Number and nature of ADR reports
Detection and management
Individual case reports of suspected ADRs are the primary source of data to detect the unexpected harm caused by medications. This information is vital to effectively manage and reduce the severity of harm due to medications.
Spontaneous reporting system at HMC facilitates timely detection of unknown ADRs. The process of ADR detection 
Good PV practices and risk reduction strategies
A set of measures have been developed by MSQC to facilitate and enhance the PV practices at HMC: All healthcare professionals joining HMC are scheduled for a mandatory medication safety educational session. Other activities include.
• Encourage, educate and support healthcare professionals and patients to report all suspected ADRs; • Review the reports for accuracy and completeness;
• Raise awareness about the importance of proper documentation; • Provide feedback to the reporters; • Maintain the confidentiality of data about the reporter and patient; • Assess benefit-to-risk ratio; • Provide medication safety updates and recommendations through a monthly newsletter; • Follow the standards and policies set by the MoPH, Qatar.
These initiatives have improved the medication safety practices at HMC resulting in changes in policies of look-alike sound-alike drugs, use of high-alert medications, label change for neuromuscular blockers etc.
Challenges
Despite the substantial progress made over the last few years, PV systems across the world still face a number of challenges with underreporting being one of them. It often delays the response process such as changing labels, issuing warnings and withdrawing drugs, and thereby compromising patient safety. Factors contributing to underreporting include most notably ignorance, lack of interest or time to report, fear of consequences, judgment bias, and belief that all drugs in the market are safe. [19] . A questionnaire-based study [20] to assess the knowledge, attitude, and barriers to ADR reporting among pharmacists in HMC revealed that although majority of pharmacists showed positive attitude towards ADR reporting, a considerable number exhibited lack of knowledge about ADRs, how to report, and what to report. Approximately 60% of the pharmacists responded did not report any ADR over the previous 12 months, mostly due to lack of time, busy schedule, cultural issues, and lack of awareness about what to report. Pharmacists also revealed that they did not receive any feedback to their previous reports, discouraging to report future incidents. Poor knowledge and lack of engagement of general public and patients towards PV practices were also among the challenges noted during the study. The findings were similar to what has been reported in other studies from the region and further afield [19, [21] [22] [23] . Hence, strategies need to be focused towards creating awareness among pharmacists about ADRs and importance of reporting.
Conclusion
Clear understanding of the characteristics and knowledge of patient safety practices are cornerstone to PV activities. As in other developing countries, PV in Qatar is evolving rapidly. Spontaneous reporting, transparency and active surveillance are new advancements in the reporting system at HMC. Further developments aim at automatic signal generation, patient reporting, and educational interventions to healthcare professionals and patients, to enhance the quality of ADR reports.
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